Hikma Pharmaceuticals Plc Through Its Affiliate Launches Prefilled Syringe Capability In The US Market

  • Sep 17, 2019 BST
  • Team Kalkine

Hikma Pharmaceuticals Plc (LSE: HIK) through its affiliate, Hikma Pharmaceuticals USA Inc, has launched a new prefilled syringe capability in the US market. The first Hikma medicine available in prefilled syringe form is Heparin Sodium Injection, USP, 5000 Units/mL, which are indicated for Prophylaxis and treatment of venous thrombosis besides many other symptoms. The prefilled syringe is ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk.

On 17th September 2019, at the time of writing, GMT 12.35 PM, HIK shares were trading at GBX 1,983.50, up by 46.50 points or 2.40% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK